Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk reported a quarterly beat and raised full-year guidance, now expecting adjusted sales and operating profit to be down 0% to flat (improving from a prior -4% to -12% range) at constant exchange rates. However, analysts noted the outperformance was helped by rebate-related and other temporary factors, with obesity drug sales broadly in line and oral Wegovy slightly missing. Investors also reacted to a mixed clinical readout for the next-gen drug CagriSema and the intensifying GLP-1 competition from Eli Lilly, with Novo’s ADRs down ~6% after hours following the results.

Analysis

The key issue is not this quarter's print; it's that the market is still paying for a durable obesity franchise while the company is increasingly behaving like a maturating incumbent. Temporary margin support from rebates can mask underlying deceleration, which means the next 1-2 earnings cycles are more likely to bring estimate cuts than upgrades unless prescription momentum re-accelerates materially. That creates a classic multiple-compression setup: even if revenue does not collapse, a lower-growth profile can justify a materially lower earnings multiple than the stock had at peak optimism.

Relative value still points to Eli Lilly as the cleaner winner. In winner-take-most therapeutic categories, the company with the more convincing pipeline and the stronger U.S. share trajectory tends to capture the lion's share of incremental formulary favorability, physician attention, and patient persistence. If Novo is forced to defend share through price/rebate actions, the second-order effect is margin dilution and less room to fund the next wave of R&D, which further widens the competitive gap versus Lilly over the next 6-18 months.

The contrarian case is that the street may already be discounting a bad outcome for Novo, so the stock can bounce on any sign that the pill rollout is translating into durable demand rather than just early-adopter noise. The thesis is falsified if U.S. prescription growth accelerates for multiple months, if consensus stops cutting 2026 revenue estimates, or if the next pipeline readout re-establishes confidence in the long-term growth stack. Absent that, the likely path is a series of lower highs: immediate post-print weakness, 1-3 month estimate reset, and a longer-term de-rating if the pipeline remains second-best.

Key Decisions for Investors

• Short NVO ADR on any relief rally over the next 1-2 weeks; use the post-earnings bounce to get better entry rather than chasing the after-hours move. Risk/reward favors downside over 1-3 months as analysts model out slower U.S. share gains and less pipeline optionality; cover if U.S. script data materially inflects higher or management raises 2026 growth assumptions.
• Initiate a long LLY / short NVO pair trade for a 3-6 month horizon. This isolates relative share gain and pipeline credibility while reducing category beta; the trade works if Lilly continues to win formulary and prescribing share, and is invalidated if Novo's oral Wegovy and next-gen pipeline show a sustained step-change in adoption.
• If using options, buy a 3-6 month NVO put spread on strength rather than outright puts. The position is best when implied vol is not excessively rich; the spread protects against a sharp short-covering rally while still expressing the view that consensus revisions have further to fall.